;PMID: 10767358
;source_file_566.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:41..125] = [t:41..125]
;2)section:[e:129..206] = [t:129..206]
;3)section:[e:210..297] = [t:210..297]
;4)sentence:[e:301..440] = [t:301..440]
;5)sentence:[e:441..530] = [t:441..530]
;6)sentence:[e:531..690] = [t:531..690]
;7)sentence:[e:691..862] = [t:691..862]
;8)sentence:[e:863..990] = [t:863..990]
;9)sentence:[e:991..1118] = [t:991..1118]
;10)sentence:[e:1119..1305] = [t:1119..1305]
;11)section:[e:1307..1531] = [t:1307..1531]
;12)section:[e:1535..1580] = [t:1535..1580]

;section 0 Span:0..36
;Oncol Rep  2000 May-Jun;7(3):497-500
(SEC
  (FRAG (DT:[0..5] Oncol) (NNP:[6..9] Rep) (CD:[11..15] 2000) (NNP:[16..18] Ma)
        (::[18..24] y-Jun;) (CD:[24..25] 7) (NN:[25..26] -LRB-) (NN:[26..27] 3)
        (NN:[27..28] -RRB-) (::[28..29] :) (CD:[29..31] 49) (::[31..36] 7-500)))

;sentence 1 Span:41..125
;Screening of human bladder carcinomas for the presence of Ha-ras codon 12 
;mutation.
;[60..78]:malignancy:"bladder carcinomas"
;[99..105]:gene-rna:"Ha-ras"
;[106..114]:variation-location:"codon 12"
;[116..124]:variation-event:"mutation"
(SENT
  (NP-HLN
    (NP (NN:[41..50] Screening))
    (PP (IN:[51..53] of)
      (NP (JJ:[54..59] human)
         (NN:[60..67] bladder) (NNS:[68..78] carcinomas)))
    (PP (IN:[79..82] for)
      (NP
        (NP (DT:[83..86] the) (NN:[87..95] presence))
        (PP (IN:[96..98] of)
          (NP (NN:[99..105] Ha-ras)
            (NML (NN:[106..111] codon) (CD:[112..114] 12))
            (NN:[116..124] mutation)))))
    (.:[124..125] .)))

;section 2 Span:129..206
;Cattan N, Saison-Behmoaras T, Mari B, Mazeau C, Amiel JL, Rossi B, Gioanni
;J.
(SEC
  (FRAG (NNP:[129..135] Cattan) (NNP:[136..137] N) (,:[137..138] ,)
        (NNP:[139..144] Saiso) (NNP:[144..155] n-Behmoaras) (NNP:[156..157] T)
        (,:[157..158] ,) (NNP:[159..163] Mari) (NNP:[164..165] B)
        (,:[165..166] ,) (NNP:[167..173] Mazeau) (NNP:[174..176] C,)
        (NNP:[177..182] Amiel) (NNP:[183..185] JL) (,:[185..186] ,)
        (NNP:[187..192] Rossi) (NNP:[193..194] B) (,:[194..195] ,)
        (NNP:[196..203] Gioanni) (NNP:[204..206] J.)))

;section 3 Span:210..297
;Laboratoire de Cancerologie du Centre Antoine Lacassagne, 06107 Nice Cedex
;02,  France.
(SEC
  (FRAG (NNP:[210..221] Laboratoire) (IN:[222..224] de)
        (NNP:[225..237] Cancerologie) (NNP:[238..240] du)
        (NNP:[241..247] Centre) (NNP:[248..255] Antoine)
        (NNP:[256..266] Lacassagne) (,:[266..267] ,) (CD:[268..273] 06107)
        (NNP:[274..278] Nice) (NNP:[279..284] Cedex) (CD:[285..287] 02)
        (,:[287..288] ,) (NNP:[290..296] France) (.:[296..297] .)))

;sentence 4 Span:301..440
;Contradictory results were obtained from previous studies aiming at defining
;the  frequency of Ha-ras codon 12 mutations in bladder tumors.
;[396..402]:gene-rna:"Ha-ras"
;[403..411]:variation-location:"codon 12"
;[412..421]:variation-event:"mutations"
;[425..439]:malignancy:"bladder tumors"
(SENT
  (S
    (NP-SBJ-1 (JJ:[301..314] Contradictory) (NNS:[315..322] results))
    (VP (VBD:[323..327] were)
      (VP (VBN:[328..336] obtained)
        (NP-1 (-NONE-:[336..336] *))
        (PP (IN:[337..341] from)
          (NP
            (NP (JJ:[342..350] previous) (NNS:[351..358] studies))
            (VP (VBG:[359..365] aiming)
              (PP (IN:[366..368] at)
                (S-NOM
                  (NP-SBJ (-NONE-:[368..368] *))
                  (VP (VBG:[369..377] defining)
                    (NP
                      (NP (DT:[378..381] the) (NN:[383..392] frequency))
                      (PP (IN:[393..395] of)
                        (NP (NN:[396..402] Ha-ras)
                          (NML (NN:[403..408] codon) (CD:[409..411] 12))
                          (NNS:[412..421] mutations)))
                      (PP-LOC (IN:[422..424] in)
                        (NP (NN:[425..432] bladder) (NNS:[433..439] tumors))))))))))))
    (.:[439..440] .)))

;sentence 5 Span:441..530
;Differences in the  sensitivities of the methods used could account for this
;discrepancy.
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[441..452] Differences))
      (PP (IN:[453..455] in)
        (NP
          (NP (DT:[456..459] the) (NNS:[461..474] sensitivities))
          (PP (IN:[475..477] of)
            (NP
              (NP (DT:[478..481] the) (NNS:[482..489] methods))
              (VP (VBN:[490..494] used)
                (NP (-NONE-:[494..494] *))))))))
    (VP (MD:[495..500] could)
      (VP (VB:[501..508] account)
        (PP-CLR (IN:[509..512] for)
          (NP (DT:[513..517] this) (NN:[518..529] discrepancy)))))
    (.:[529..530] .)))

;sentence 6 Span:531..690
;In this  study, we reevaluated the frequency of Ha-ras codon 12 mutations in
;a series of  87 human bladder tumors using a combination of two different
;methods.
;[579..585]:gene-rna:"Ha-ras"
;[586..594]:variation-location:"codon 12"
;[595..604]:variation-event:"mutations"
;[630..644]:malignancy:"bladder tumors"
(SENT
  (S
    (PP (IN:[531..533] In)
      (NP (DT:[534..538] this) (NN:[540..545] study)))
    (,:[545..546] ,)
    (NP-SBJ (PRP:[547..549] we))
    (VP (VBD:[550..561] reevaluated)
      (NP
        (NP (DT:[562..565] the) (NN:[566..575] frequency))
        (PP (IN:[576..578] of)
          (NP (NN:[579..585] Ha-ras)
            (NML (NN:[586..591] codon) (CD:[592..594] 12))
            (NNS:[595..604] mutations)))
        (PP (IN:[605..607] in)
          (NP
            (NP (DT:[608..609] a) (NN:[610..616] series))
            (PP (IN:[617..619] of)
              (NP (CD:[621..623] 87) (JJ:[624..629] human)
                 (NN:[630..637] bladder) (NNS:[638..644] tumors))))))
      (S-MNR
        (NP-SBJ (-NONE-:[644..644] *))
        (VP (VBG:[645..650] using)
          (NP
            (NP (DT:[651..652] a) (NN:[653..664] combination))
            (PP (IN:[665..667] of)
              (NP (CD:[668..671] two) (JJ:[672..681] different)
                  (NNS:[682..689] methods)))))))
    (.:[689..690] .)))

;sentence 7 Span:691..862
;The first  was derived from the protocol of Ooi et al and consisted in a
;one-step  allele-specific polymerase chain reaction using mismatched primers
;in two  separate PCR.
(SENT
  (S
    (NP-SBJ-1 (DT:[691..694] The) (JJ:[695..700] first))
    (VP
      (VP (VBD:[702..705] was)
        (VP (VBN:[706..713] derived)
          (NP-1 (-NONE-:[713..713] *))
          (PP (IN:[714..718] from)
            (NP
              (NP (DT:[719..722] the) (NN:[723..731] protocol))
              (PP (IN:[732..734] of)
                (NP (NNP:[735..738] Ooi) (FW:[739..741] et) (FW:[742..744] al)))))))
      (CC:[745..748] and)
      (VP (VBD:[749..758] consisted)
        (PP (IN:[759..761] in)
          (NP
            (NP (DT:[762..763] a)
              (NML (CD:[764..767] one) (HYPH:[767..768] -) (NN:[768..772] step))
              (ADJP (NN:[774..780] allele) (HYPH:[780..781] -)
                    (JJ:[781..789] specific))
              (NN:[790..800] polymerase) (NN:[801..806] chain)
               (NN:[807..815] reaction))
            (VP (VBG:[816..821] using)
              (NP (JJ:[822..832] mismatched) (NNS:[833..840] primers))
              (PP (IN:[841..843] in)
                (NP (CD:[844..847] two) (JJ:[849..857] separate)
                    (NN:[858..861] PCR))))))))
    (.:[861..862] .)))

;sentence 8 Span:863..990
;This method is very rapid and highly sensitive, detecting the  presence of
;minor populations (less than 10%) of mutant alleles.
(SENT
  (S
    (NP-SBJ (DT:[863..867] This) (NN:[868..874] method))
    (VP (VBZ:[875..877] is)
      (ADJP-PRD
        (ADJP (RB:[878..882] very) (JJ:[883..888] rapid))
        (CC:[889..892] and)
        (ADJP (RB:[893..899] highly) (JJ:[900..909] sensitive)))
      (,:[909..910] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[910..910] *))
        (VP (VBG:[911..920] detecting)
          (NP
            (NP (DT:[921..924] the) (NN:[926..934] presence))
            (PP (IN:[935..937] of)
              (NP
                (NP (JJ:[938..943] minor) (NNS:[944..955] populations)
                  (PRN (-LRB-:[956..957] -LRB-)
                    (ADJP (JJS:[957..961] less)
                      (PP (IN:[962..966] than)
                        (NP (CD:[967..969] 10) (NN:[969..970] %))))
                    (-RRB-:[970..971] -RRB-)))
                (PP (IN:[972..974] of)
                  (NP (JJ:[975..981] mutant) (NNS:[982..989] alleles)))))))))
    (.:[989..990] .)))

;sentence 9 Span:991..1118
;The second  strategy consisted in screening all tumors using natural
;restriction fragment  length polymorphism (RFLP) analysis.
;[1039..1045]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ (DT:[991..994] The) (JJ:[995..1001] second)
            (NN:[1003..1011] strategy))
    (VP (VBD:[1012..1021] consisted)
      (PP (IN:[1022..1024] in)
        (S-NOM
          (NP-SBJ (-NONE-:[1024..1024] *))
          (VP (VBG:[1025..1034] screening)
            (NP (DT:[1035..1038] all) (NNS:[1039..1045] tumors))
            (S-MNR
              (NP-SBJ (-NONE-:[1045..1045] *))
              (VP (VBG:[1046..1051] using)
                (NP (JJ:[1052..1059] natural)
                  (NML
                    (NML (NN:[1060..1071] restriction)
                         (NN:[1072..1080] fragment) (NN:[1082..1088] length)
                         (NN:[1089..1101] polymorphism))
                    (NML (-LRB-:[1102..1103] -LRB-) (NN:[1103..1107] RFLP)
                         (-RRB-:[1107..1108] -RRB-)))
                  (NN:[1109..1117] analysis))))))))
    (.:[1117..1118] .)))

;sentence 10 Span:1119..1305
;The two methods were in complete  concordance and enabled us to show that
;only one out of 87 primary bladder  carcinomas (1%) exhibited the mutation,
;in accordance with previous studies.
;[1212..1239]:malignancy:"primary bladder  carcinomas"
(SENT
  (S
    (NP-SBJ (DT:[1119..1122] The) (CD:[1123..1126] two)
            (NNS:[1127..1134] methods))
    (VP
      (VP (VBD:[1135..1139] were)
        (PP-PRD (IN:[1140..1142] in)
          (NP (JJ:[1143..1151] complete) (NN:[1153..1164] concordance))))
      (CC:[1165..1168] and)
      (VP (VBD:[1169..1176] enabled)
        (NP-1 (PRP:[1177..1179] us))
        (S-ADV
          (NP-SBJ-1 (-NONE-:[1179..1179] *))
          (VP (TO:[1180..1182] to)
            (VP (VB:[1183..1187] show)
              (SBAR (IN:[1188..1192] that)
                (S
                  (NP-SBJ
                    (NP
                      (ADVP (RB:[1193..1197] only))
                      (CD:[1198..1201] one))
                    (PP (IN:[1202..1205] out)
                      (PP (IN:[1206..1208] of)
                        (NP (CD:[1209..1211] 87)
                           (JJ:[1212..1219] primary) (NN:[1220..1227] bladder)
                           (NNS:[1229..1239] carcinomas))))
                    (PRN (-LRB-:[1240..1241] -LRB-)
                      (NP (CD:[1241..1242] 1) (NN:[1242..1243] %))
                      (-RRB-:[1243..1244] -RRB-)))
                  (VP (VBD:[1245..1254] exhibited)
                    (NP (DT:[1255..1258] the) (NN:[1259..1267] mutation)))))
              (,:[1267..1268] ,)
              (PP (IN:[1269..1271] in)
                (NP
                  (NP (NN:[1272..1282] accordance))
                  (PP (IN:[1283..1287] with)
                    (NP (JJ:[1288..1296] previous) (NNS:[1297..1304] studies))))))))))
    (.:[1304..1305] .)))

;section 11 Span:1307..1531
;These results strongly suggest that, even if minor cell populations
;overexpress  codon 12 Ha-ras mutation, the analysis of this mutation cannot
;be used to screen  potentially invasive transitional cell tumors of the
;bladder.
;[1388..1396]:variation-location:"codon 12"
;[1397..1403]:gene-rna:"Ha-ras"
;[1404..1412]:variation-event:"mutation"
;[1430..1443]:variation-event:"this mutation"
;[1470..1530]:malignancy:"potentially invasive transitional cell tumors of the
;bladder"
(SEC
  (S
    (NP-SBJ (DT:[1307..1312] These) (NNS:[1313..1320] results))
    (ADVP (RB:[1321..1329] strongly))
    (VP (VBP:[1330..1337] suggest)
      (SBAR (IN:[1338..1342] that) (,:[1342..1343] ,)
        (S
          (ADVP (RB:[1344..1348] even)
            (SBAR (IN:[1349..1351] if)
              (S
                (NP-SBJ (JJ:[1352..1357] minor) (NN:[1358..1362] cell)
                        (NNS:[1363..1374] populations))
                (VP (VBP:[1375..1386] overexpress)
                  (NP
                    (NML (NN:[1388..1393] codon) (CD:[1394..1396] 12))
                    (NN:[1397..1403] Ha-ras) (NN:[1404..1412] mutation))))))
          (,:[1412..1413] ,)
          (NP-SBJ-1
            (NP (DT:[1414..1417] the) (NN:[1418..1426] analysis))
            (PP (IN:[1427..1429] of)
              (NP (DT:[1430..1434] this) (NN:[1435..1443] mutation))))
          (VP (MD:[1444..1450] cannot)
            (VP (VB:[1451..1453] be)
              (VP (VBN:[1454..1458] used)
                (NP-1 (-NONE-:[1458..1458] *))
                (S-ADV
                  (NP-SBJ (-NONE-:[1458..1458] *))
                  (VP (TO:[1459..1461] to)
                    (VP (VB:[1462..1468] screen)
                      (NP
                        (NP
                          (ADJP (RB:[1470..1481] potentially)
                                (JJ:[1482..1490] invasive))
                          (JJ:[1491..1503] transitional) (NN:[1504..1508] cell)
                           (NNS:[1509..1515] tumors))
                        (PP (IN:[1516..1518] of)
                          (NP (DT:[1519..1522] the) (NN:[1523..1530] bladder)))))))))))))
    (.:[1530..1531] .)))
;ERROR_Entity in section[1388..1396]:variation-location "codon 12"
;ERROR_Entity in section[1397..1403]:gene-rna "Ha-ras"
;ERROR_Entity in section[1404..1412]:variation-event "mutation"
;ERROR_Entity in section[1430..1443]:variation-event "this mutation"
;ERROR_Entity in section[1470..1530]:malignancy "potentially invasive
;transitional cell tumors of the bladder"

;section 12 Span:1535..1580
;PMID: 10767358 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1535..1539] PMID) (::[1539..1540] :) (CD:[1541..1549] 10767358)
        (NN:[1550..1551] -LSB-) (NNP:[1551..1557] PubMed) (::[1558..1559] -)
        (NN:[1560..1567] indexed) (IN:[1568..1571] for)
        (NNP:[1572..1580] MEDLINE-RSB-)))
